Key Highlights

  • Fiscal third quarter 2026 Net Income reached CAD 105.5 million, reported August 11, 2026, against a CAD 6.3 million loss a year earlier, driven chiefly by non-cash Fair Value gains on preferred shares.
  • Net Revenue came in at CAD 105.8 million, up 49%, while adjusted EBITDA rose 136% to CAD 13.4 million from CAD 5.7 million for the quarter ended June 30, 2026.
  • Published market data lists a 1 year EPS change of 821.77%, a figure that reflects a loss-making base and a fair value gain rather than operating profit.
  • Cash and short-term investments were CAD 11.7 million, Liquidity including Credit facilities totaled CAD 49.1 million, and total liabilities stood at CAD 334.8 million.

Remeasurement Gains Inflate the Headline Profit

The company, listed as Organigram Global (NASDAQ:OGI), produces cannabis in Canada. Fiscal Q3 net income of CAD 105.5 million came chiefly from non-cash gains tied to the fair value of preferred shares, which sit outside core production. When an instrument is remeasured, a drop in its value is booked as a gain, and that effect can reverse in later periods. Adjusted EBITDA of CAD 13.4 million offers a cleaner read on operations. The release shows dollar signs without naming a currency, and Organigram reports in Canadian dollars, so the CAD label is inferred. By simple arithmetic, adjusted EBITDA equaled about 12.7% of net revenue, while net income roughly matched net revenue, which underlines how unusual the gain is.

Sanity Group Deal Adds Revenue and Market Share

The Sanity Group Acquisition closed on April 15, 2026 and contributed about CAD 40 million of net revenue during the quarter. Adjusted gross Margin reached CAD 39.1 million, or 37% of net revenue, against selling, general and administrative expense of CAD 32.7 million. Management said it remains on track for fiscal year net revenue above CAD 350 million. Company data place the Business first in Canada for vapes, milled flower and concentrates as of June 2026, and second in flower and pre-rolls. Edibles ranked third and beverages fourth. The purchase also brought German exposure and integration work to manage.

The 821.77% Caveat, Cash Flow and a CFO Exit

The 821.77% EPS change comes from published market data and remains unverified. Growth off a negative base looks extreme, and the swing from a CAD 6.3 million loss to a fair value gain is likely on a GAAP basis, though the basis is not confirmed. Free cash flow was negative CAD 3.9 million and Operating Cash Flow was negative CAD 4.3 million. Total liabilities climbed from CAD 213.1 million at September 30, 2025, and CFO Paolo De Luca is leaving the company.

Where Things Stand

Largely no. The 821.77% EPS jump mainly reflects a non-cash fair value gain set against a loss-making base, not a rise of that size in operating earnings. Organigram Global (NASDAQ:OGI) does show real operating progress, with net revenue up 49%, adjusted EBITDA up 136% and a larger Canadian footprint after the Sanity Group deal, yet cash flow was negative and liabilities grew. Investors may watch the fiscal fourth quarter report, which has no confirmed date, along with free cash flow, the CFO succession, Sanity integration progress and whether fair value gains reverse. Management's fiscal net revenue outlook above CAD 350 million is not a guarantee.